---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-124881"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2024-12-03T23:59:59+00:00"
generated_at: "2026-05-29T09:50:09.148880+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Coherus to divest UDENYCA franchise to Intas for up to $558.4M; plans to repay convertible notes

## Summary
- Upfront cash $483.4M (subject to inventory adj.) plus up to $75M in net sales milestones ($37.5M each at $300M and $350M thresholds).
- Proceeds to fully repay $230M 1.5% convertible notes due April 2026 and buy out $49.1M royalty obligation on UDENYCA.
- Post-close cash runway over 2 years; focus shifts to immuno-oncology pipeline (LOQTORZI, casdozokitug, CHS-114).
- Transaction requires shareholder approval, HSR, CFIUS; expected close Q1 2025; board unanimously recommends.
- Coherus to provide Q4 2024 sales and Q1 2025 cash guidance in early January 2025.

## SEC filing metadata
- accession: 0001104659-24-124881
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2024-12-03T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/0001104659-24-124881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000110465924124881/tm2429853d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-124881
- JSON: https://secwatch.observer/filing/0001104659-24-124881.json
- Plain text: https://secwatch.observer/filing/0001104659-24-124881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.